Immutep (IMMP) has released an update.
Immutep’s latest clinical trial, TACTI-003, shows promising results for its novel immunotherapy, efti, when combined with KEYTRUDA in treating head and neck cancer, with significantly improved response rates, notably in patients with high PD-L1 expression. The combination therapy not only proved to be efficacious but also maintained a favorable safety profile, demonstrating a potential new avenue for cancer treatment without compromising patient safety.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
